IR-Med, Inc. (IRME) Financial Statements (2025 and earlier)

Company Profile

Business Address C/O ABOUDI LEGAL GROUP PLLC, 745 5TH AVE
NEW YORK, NY 10151
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments767,0003,002,0002,815,000
Cash and cash equivalents767,0003,002,0002,815,000
Receivables81,00055,00067,000
Total current assets:848,0003,057,0002,882,000
Noncurrent Assets
Operating lease, right-of-use asset84,000155,000 
Property, plant and equipment56,00071,00031,000
Other undisclosed noncurrent assets11,00011,00030,000
Total noncurrent assets:151,000237,00061,000
TOTAL ASSETS:999,0003,294,0002,943,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:473,000500,000395,000
Employee-related liabilities129,000
Accounts payable64,00068,00061,000
Accrued liabilities160,000132,000140,000
Other undisclosed accounts payable and accrued liabilities249,000300,00065,000
Due to related parties162,000 
Total current liabilities:473,000662,000395,000
Noncurrent Liabilities
Long-term debt and lease obligation, including:  40,000 
Other undisclosed long-term debt and lease obligation  40,000 
Liabilities, other than long-term debt   177,000
Due to related parties 177,000
Other undisclosed noncurrent liabilities 161,000  
Total noncurrent liabilities: 161,00040,000177,000
Other undisclosed liabilities   
Total liabilities:634,000702,000572,000
Equity
Equity, attributable to parent365,0002,592,0002,371,000
Common stock69,00068,00064,000
Additional paid in capital15,135,00012,454,0007,503,000
Accumulated deficit(14,839,000)(9,930,000)(5,196,000)
Total equity:365,0002,592,0002,371,000
TOTAL LIABILITIES AND EQUITY:999,0003,294,0002,943,000

Income Statement (P&L) (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Operating expenses(4,911,000)(4,762,000)(3,675,000)
Operating loss:(4,911,000)(4,762,000)(3,675,000)
Nonoperating income (expense)2,00028,000(41,000)
Other nonoperating expense (1,000)(1,000)(1,000)
Interest and debt expense  (6,000)(5,000)
Loss from continuing operations before equity method investments, income taxes:(4,909,000)(4,740,000)(3,721,000)
Other undisclosed income from continuing operations before income taxes9,818,0009,474,0005,000
Income (loss) from continuing operations:4,909,0004,734,000(3,716,000)
Loss before gain (loss) on sale of properties:(3,716,000)
Net income (loss):4,909,0004,734,000(3,716,000)
Other undisclosed net loss attributable to parent(9,818,000)(9,468,000) 
Net loss available to common stockholders, diluted:(4,909,000)(4,734,000)(3,716,000)

Comprehensive Income (USD)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net income (loss):4,909,0004,734,000(3,716,000)
Comprehensive income (loss), net of tax, attributable to parent:4,909,0004,734,000(3,716,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: